| Pulmonary Arterial Hypertension |
1 |
1 |
| Heart Failure (HF) |
0 |
0.67 |
| Right Heart Catheterization |
0 |
0.56 |
| Hypertension |
0 |
0.5 |
| Pulmonary Hypertension |
0 |
0.46 |
| Heart |
0 |
0.4 |
| Cardiac MRI |
0 |
0.34 |
| Prostacyclin |
0 |
0.34 |
| Cardiovascular Imaging |
0 |
0.31 |
| Catheterization |
0 |
0.29 |
| Kansas |
0 |
0.29 |
| Myocardial Infarction (MI) |
0 |
0.27 |
| Clinical Research |
0 |
0.23 |
| Hemodynamics |
0 |
0.23 |
| Biomarker |
0 |
0.17 |
| Endothelin Receptor Antagonists |
0 |
0.12 |
| Artery |
0 |
0.11 |
| Biologic Therapy |
0 |
0.11 |
| Echocardiography |
0 |
0.11 |
| Europe |
0 |
0.11 |
| Receptors |
0 |
0.11 |
| Washington |
0 |
0.11 |
| CT Scan |
0 |
0.1 |
| Methamphetamine |
0 |
0.1 |
| B-Type Natriuretic Peptide |
0 |
0.08 |
| Renal Disease |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.08 |
| Chronic Kidney Disease |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Addiction |
0 |
0.06 |
| Allergy |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Board Certification |
0 |
0.06 |
| Bone |
0 |
0.06 |
| Brain |
0 |
0.06 |
| Dyspnea |
0 |
0.06 |
| Face |
0 |
0.06 |
| Generics |
0 |
0.06 |
| Kidney |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Nitric Oxide |
0 |
0.06 |
| Precision Medicine |
0 |
0.06 |
| Preventive Screening |
0 |
0.06 |
| Professional Development |
0 |
0.06 |
| Proteomics |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Scan |
0 |
0.06 |
| Thorax |
0 |
0.06 |
| Tolerance |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |
| Genomic Medicine |
0 |
0.04 |
| Scleroderma |
0 |
0.04 |